Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10965166 | Vaccine | 2014 | 5 Pages |
Abstract
This prospective study aimed to investigate the immune responses and safety of an influenza vaccine in vaccine-naïve infants aged 6-12 months, and was conducted from November 2010 to May 2011. Fifty-nine infants aged 6-12 months received two doses of trivalent inactivated influenza vaccine 4 weeks apart. Hemagglutination inhibition titers were measured 4 weeks after the two doses of study vaccine. Based on the assumption that a hemagglutination inhibition titer of 1:40 or greater against the antigen would be protective in adults, two doses of the study vaccine generated a protective immune response of 63.2% against influenza A(H1N1), 82.5% against influenza A(H3N2) and 38.6% against influenza B viruses in infants aged 6-12 months. The geometric mean fold rises against influenza type A and B viruses also met the European Medicines Agency criteria for flu vaccines. The solicited events within 7 days after vaccination were mild in intensity. No deaths or adverse events such as optic neuritis, cranial neuropathy, and brachial neuropathy or Guillain-Barre syndrome were reported. Two doses of inactivated influenza vaccine were well tolerated and induced a protective immune response against influenza in infants aged 6-12 months.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Kao-Pin Hwang, Yu-Lung Hsu, Tsung-Hsueh Hsieh, Hsiao-Chuan Lin, Ting-Yu Yen, Hsiu-Mei Wei, Hung-Chih Lin, An-Chyi Chen, Julie Chi Chow, Li-Min Huang,